Effects of maximum dose on local control after stereotactic body radiotherapy for oligometastatic tumors of colorectal cancer
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0313438 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Su Jin Kang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Colorectal Cancer Center, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. Hauptthemen laut MEDLINE: Radiosurgery, Colorectal Neoplasms, Radiotherapy Dosage, Liver Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Research Foundation of Korea grant funded by the Korean government.
Abstract (Originalsprache)
This study aimed to identify radiotherapy dosimetric parameters related to local failure (LF)-free survival (LFFS) in patients with lung and liver oligometastases from colorectal cancer treated with stereotactic body radiotherapy (SBRT). We analyzed 75 oligometastatic lesions in 55 patients treated with SBRT between January 2014 and December 2021. There was no constraint or intentional increase in maximum dose. LF was defined as the progression of the treated lesion until the last follow-up or death. The dose distributions were recalculated using Monte Carlo-based algorithms. The significance of the planning target volume (PTV) biologically effective dose (BED) 10s (D2, D95, D98, Dmean) in LFFS was evaluated using Cox regression, considering sex, age, primary cancer, tumor site, oligometastatic status, multiplicity, and either tumor size or one of the volume parameters. LF occurred in 23.4% of the lesions. Lesions showing LF received significantly lower PTV D2 (146 ± 21 vs. 164 ± 23, p = 0.006). Multivariate analysis revealed that PTV D2 (< 159 Gy 10 vs. ≥ 159 Gy 10 ) was the sole dosimetric parameter associated with LFFS. Tumors equal to or larger than the median size/volume yet receiving < 159 Gy 10 of PTV D2 showed the lowest LFFS following stratification by median PTV D2 combined with tumor size or volume parameters. The maximum dose (PTV D2) was significantly associated with LFFS after SBRT for lung and liver oligometastases from colorectal cancer. Increasing the maximum dose may be beneficial for managing larger tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Colorectal Cancer Center, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
- Department of Radiation Oncology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
- Department of Oncology/Hematology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
- Department of Pathology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea.
ORCID-Profile: Jongmoo Park, Min Kyu Kang
Förderung
- The National Research Foundation of Korea grant funded by the Korean government
Zitieren
APA
Kang, S. J., Park, J., Choi, G. S., Kim, J. G., Park, J. S., Kim, H. J., Baek, J. H., Kang, B. W., Seo, A. N., Park, S. H., Bae, B. K., Kang, M. K., & Park, S. Y. (2025). Effects of maximum dose on local control after stereotactic body radiotherapy for oligometastatic tumors of colorectal cancer. PLOS ONE. https://doi.org/10.1371/journal.pone.0313438
Vancouver
Kang SJ, Park J, Choi GS, Kim JG, Park JS, Kim HJ, et al. Effects of maximum dose on local control after stereotactic body radiotherapy for oligometastatic tumors of colorectal cancer. PLOS ONE. 2025. doi:10.1371/journal.pone.0313438
BibTeX
@article{Kang2025,
author = {Kang, Su Jin and Park, Jongmoo and Choi, Gyu-Seog and Kim, Jong Gwang and Park, Jun Seok and Kim, Hye Jin and Baek, Jin Ho and Kang, Byung Woog and Seo, An Na and Park, Shin-Hyung and Bae, Bong Kyung and Kang, Min Kyu and Park, Soo Yeun},
title = {Effects of maximum dose on local control after stereotactic body radiotherapy for oligometastatic tumors of colorectal cancer},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0313438}
}
EUVIMED